FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial. PMID 40696453 · Mol Cancer · 2025-Jul-22 Study meets most criteria but randomization status is not explicitly confirmed in the provided metadata; therefore, eligibility cannot be definitively determined. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Multiply doses of FDC of rosuvastatin and ezetimibe versus rosuvastatin monotherapy in Chinese patients with hypercholesterolemia (ROSE-CH): multicenter, randomized-controlled trial. PMID 40696391 · Lipids Health Dis · 2025-Jul-22 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD: The VICTORION-Mono Randomized Clinical Trial. PMID 40392667 · J Am Coll Cardiol · 2025-Jul-22 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703. PMID 40305657 · Blood Adv · 2025-Jul-22 The abstract describes a secondary analysis of a subgroup (patients ≥70 years) from a Phase III randomized trial (BMT CTN 1703). While it is a human oncology RCT with a time-to-event endpoint (GRFS), the interventions (PTCy, Tac/MTX) are immunosuppressive regimens for GVHD prophylaxis, not a drug-containing intervention for the hematologic malignancy itself. The endpoint (GRFS) is a composite of GVHD control and relapse, not a traditional drug-efficacy endpoint like OS or PFS for the cancer. Therefore, it does not meet the criterion for a 'drug-containing intervention' for the malignant neoplasm. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Statin use and survival in CLL/SLL treated with ibrutinib: pooled analysis of 4 randomized controlled trials. PMID 40266025 · Blood Adv · 2025-Jul-22 The record is a pooled analysis of four randomized controlled trials (RESONATE, RESONATE-2, iLLUMINATE, HELIOS), but the specific trials are not individually described with sufficient detail (e.g., phase, primary endpoint, drug intervention for the trial itself). The analysis focuses on the association of statin use with outcomes, which is a secondary analysis, not the original primary efficacy report of a trial. Additionally, while statin use is analyzed, the primary drug intervention in the trials is ibrutinib, but the report itself is not a primary trial result report; it is a post-hoc/pooled analysis of existing trial data. The phase of the trials is not explicitly stated in the metadata as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma. PMID 40448574 · J Clin Oncol · 2025-Jul-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study. PMID 40448572 · J Clin Oncol · 2025-Jul-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA-IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial. PMID 40682106 · BMC Med · 2025-Jul-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Impact of Ecological Momentary Assessment Participation on Short-Term Smoking Cessation: quitSTART Ecological Momentary Assessment Incentivization Randomized Trial. PMID 40680166 · J Med Internet Res · 2025-Jul-18 The study is a randomized controlled trial in humans, but it is not an oncology trial (smoking cessation), does not involve a drug intervention, and does not use a time-to-event endpoint (primary outcome is abstinence at fixed time points, not a survival or time-to-event analysis). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial. PMID 39960062 · Clin Infect Dis · 2025-Jul-18 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Intraoperative parathyroid hormone monitoring to guide surgery in renal hyperparathyroidism (PEREGRINE): a protocol for a randomised multiarm surgical pilot trial. PMID 40675640 · BMJ Open · 2025-Jul-17 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Multidose Ondansetron after Emergency Visits in Children with Gastroenteritis. PMID 40673584 · N Engl J Med · 2025-Jul-17 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Moderately hypofractionated online adaptive radiotherapy (SWIFT-1) in cervical cancer patients: study protocol for a multi-centered, open-label, two-arm, phase III, randomized controlled study. PMID 40671096 · Radiat Oncol · 2025-Jul-16 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Indocyanine green fluorescence in pelvic lymph node dissection during laparoscopic radical prostatectomy: a randomized controlled trial. PMID 40670731 · Updates Surg · 2025-Jul-16 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081. PMID 40664454 · J Immunother Cancer · 2025-Jul-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The Effect of Forgiveness Psychoeducation on Forgiveness, Self-Compassion and Death Anxiety in Cancer Patients: A Randomized Controlled Trial. PMID 40663159 · Omega (Westport) · 2025-Jul-15 The record reports a randomized controlled trial in oncology patients, but it tests a non-drug intervention (forgiveness psychoeducation) and its endpoints are psychological outcomes, not time-to-event efficacy measures. Therefore, it does not meet the criteria for inclusion in the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Perioperative administration of CBM588 in colorectal cancer radical surgery: A single-center, randomized controlled trial. PMID 40633539 · Cell Rep Med · 2025-Jul-15 The study is a Phase IV randomized controlled trial in colorectal cancer with a drug intervention, but it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The endpoints are postoperative functional recovery and immune status, not survival or progression-based outcomes. Therefore, it is ineligible for the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800). PMID 40614118 · Cancer · 2025-Jul-15 The record is excluded because it does not meet the required phase criterion (one trial is Phase 3b, the other is Phase 2, and the combined record is not a single definitive Phase III/IIIb or Phase II/III trial) and lacks a time-to-event efficacy endpoint. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE study. PMID 40450840 · J Neurol Sci · 2025-Jul-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Patient-Reported Outcomes for Glabellar Line Improvement and Satisfaction With the RelabotulinumtoxinA Ready-to-Use Liquid Formulation: Data From the Phase 3 READY-1 Trial. PMID 40242960 · Aesthet Surg J · 2025-Jul-15 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Esaxerenone Plus a Renin-Angiotensin System Inhibitor or Calcium Channel Blocker for Nocturnal Hypertension: A Post Hoc Analysis. PMID 40178088 · Am J Hypertens · 2025-Jul-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial. PMID 40079683 · Int J Cancer · 2025-Jul-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Evaluation of the Efficacy and Safety of a Dual Delayed-Release Formulation of 10-mg Esomeprazole in Patients with Gastric Erosions: A Multicenter, Randomized, Double-Blind, Active-Control, Phase III Study. PMID 39949051 · Gut Liver · 2025-Jul-15 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Novel Y-Shaped Pegylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency. PMID 39607675 · J Clin Endocrinol Metab · 2025-Jul-15 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch. PMID 40678712 · World J Gastroenterol · 2025-Jul-14 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A community pharmacy-based program to enhance adherence to adjuvant endocrine therapy among breast cancer survivors (PACHA): protocol for a pilot cluster-randomized controlled trial. PMID 40660375 · Pilot Feasibility Stud · 2025-Jul-14 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Reasons for refusing high tibial osteotomy and the impact of virtual reality-based patient education: a prospective single-centre study. PMID 40660307 · J Orthop Surg Res · 2025-Jul-14 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Personalized, Texting-Based Conversational Agent to Address Sleep Disturbance in Individuals Who Have Survived Breast Cancer: Protocol for a Pilot Waitlist Randomized Controlled Trial. PMID 40658949 · JMIR Res Protoc · 2025-Jul-14 This is a protocol for a pilot randomized trial of a non-drug, digital cognitive behavioral therapy intervention for sleep disturbance in breast cancer survivors. It is not a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention, does not report efficacy results, and has no time-to-event primary or key secondary endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Influence of different photobiomodulation protocols on the prevention of chemotherapy-induced dysgeusia in breast cancer patients treated with Doxorubicin-Cyclophosphamide: a phase III, randomized, triple-blinded non-inferiority clinical trial. PMID 40658227 · Support Care Cancer · 2025-Jul-14 The record is a Phase III randomized trial in oncology with a drug intervention, but it does not have a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The endpoints are toxicity, quality of life, and other non-survival outcomes. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Surgery or radiotherapy for early-stage cancer study (SORT) target trial protocol: stereotactic ablative radiotherapy (SABR) with curative intent versus surgical resection for early-stage non-small cell lung cancer (NSCLC). PMID 40659399 · BMJ Open · 2025-Jul-13 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Impact of proactively inviting people with advanced cancer to talk about the end of life: a randomised clinical trial protocol. PMID 40659391 · BMJ Open · 2025-Jul-13 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Does propranolol have a role in cancer treatment? A systematic review of the epidemiological and clinical trial literature on beta-blockers. PMID 40652143 · J Cancer Res Clin Oncol · 2025-Jul-12 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial. PMID 40570869 · Lancet · 2025-Jul-12 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| STUDY PROTOCOL FOR A DUAL-CENTER RANDOMIZED CONTROLLED TRIAL COMPARING LAPAROSCOPIC AND OPEN 'MINOR' LIVER RESECTIONS IN UKRAINIAN COLORECTAL CANCER PATIENTS WITH LIVER METASTASES. PMID 40674155 · Exp Oncol · 2025-Jul-11 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study. PMID 40641116 · Br J Psychiatry · 2025-Jul-11 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children and Adolescents Participating in the DEN-301 Trial in Asia Pacific and Latin America. PMID 40100744 · J Infect Dis · 2025-Jul-11 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Microbiome and Metabolome Restoration After Administration of Fecal Microbiota, Live-jslm (REBYOTA) for Preventing Recurrent Clostridioides difficile Infection. PMID 39172632 · J Infect Dis · 2025-Jul-11 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Chinese patients with advanced non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials. PMID 40640844 · World J Surg Oncol · 2025-Jul-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Artificial capnothorax versus single-lung ventilation in minimally invasive esophagectomy for esophageal cancer: A randomized controlled trial. PMID 40640078 · Chin Med J (Engl) · 2025-Jul-10 The study is a randomized oncology trial with time-to-event efficacy results, but it lacks a drug-containing intervention, which is a required criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hypertensive disorders of pregnancy and perinatal outcomes: two prospective cohort studies of nulliparous women in India and Tanzania. PMID 40639854 · BMJ Glob Health · 2025-Jul-10 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Enhancing outcomes in medically inoperable early-stage NSCLC with gut-targeted antibiotics and stereotactic body radiotherapy: results from a randomized pilot study. PMID 40639850 · J Immunother Cancer · 2025-Jul-10 The report is an original result of a randomized, human oncology trial with a drug intervention and time-to-event efficacy endpoints. However, it is explicitly described as a 'pilot study', which is generally considered an early-phase (e.g., Phase II) or feasibility study, not a definitive Phase III/IIIb or Phase II/III trial. The instructions exclude early-phase studies and require explicit establishment of Phase III/IIIb or Phase II/III status, which is not met here. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Theory-based chatbot for promoting colorectal cancer screening in a community setting in Hong Kong: study protocol of a randomised controlled trial. PMID 40639841 · BMJ Open · 2025-Jul-10 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Relationship Between Third-Trimester Low Maternal Blood Pressure and Small-for-Gestational-Age Birth Weight in Pregnant Individuals With Mild Chronic Hypertension. PMID 40638923 · Obstet Gynecol · 2025-Jul-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Early-life undernutrition increases the risk of death from chronic diseases in adulthood: a population-based cohort study. PMID 40635115 · Glob Health Res Policy · 2025-Jul-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase-Targeted Approaches. PMID 40440566 · J Clin Oncol · 2025-Jul-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Intravenous Tenecteplase before Thrombectomy in Stroke. PMID 40396577 · N Engl J Med · 2025-Jul-10 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| As-Needed Albuterol-Budesonide in Mild Asthma. PMID 40388330 · N Engl J Med · 2025-Jul-10 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Reduced morbidity and mortality of cGVHD in patients who received treatment with mesenchymal stromal cells for steroid-resistant aGVHD: long-term follow-up of a randomized phase 3 trial. PMID 40635107 · Exp Hematol Oncol · 2025-Jul-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Baseline factors affecting diabetic macular oedema resolution after intravitreal dexamethasone implant treatment: post hoc analysis of the MEAD study. PMID 40634898 · BMC Ophthalmol · 2025-Jul-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| PARP Inhibitors for Metastatic CRPC: More Answers than Questions, a Systematic Review and Meta-Analysis. PMID 40732303 · Pharmaceuticals (Basel) · 2025-Jul-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |